

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A diagnostic test system ~~[[kit]]~~ for detection of a human cancer cell that expresses glypican-1, comprising:  
a binding molecule bound to human glypican-1 protein or mRNA encoding glypican-1 of a cell, wherein the binding molecule is selected from the group consisting of an antibody, ~~[[and]]~~ an antibody fragment, and a nucleic acid capable of hybridizing with the mRNA encoding glypican-1 that binds to human glypican-1, and optionally a reporting molecule attached to the binding molecule-such that a detection method allows detection of the cancer by detection of the presence of the binding molecule via detection of the reporting molecule; and  
an interpretive article associated with the binding molecule an instruction that provides information that overexpression of glypican-1 in a tissue as compared to a corresponding healthy tissue as evidenced by binding of the binding molecule to a cell is indicative of a human cancer-cell that overexpresses glypican-1.
2. (currently amended) The diagnostic test system agent of Claim 1, wherein the binding molecule comprises an antibody.
3. (currently amended) The diagnostic test system agent of Claim 2, wherein the antibody is bound to used to detect glypican-1 in a body fluid tissue section.
4. (currently amended) The diagnostic test system agent of Claim 2, wherein the antibody is labeled with a label suitable for use in imaging used to image glypican-1.
5. (currently amended) A ~~therapeutic cell treatment system~~ therapeutic cell treatment system ~~[[kit]]~~ comprising a therapeutic agent at a concentration effective to slow growth of human cancer cells identified to overexpress glypican-1 in a tissue as compared to a corresponding healthy tissue, wherein the agent comprises a molecule selected from the group consisting of a nucleic acid that hybridizes with mRNA encoding glypican-1, an antibody, and an antibody fragment that affects glypican-1 by one of binding to an extracellular region of human glypican-1,

- cleaving an extracellular region of human glypican-1, and suppressing expression of an extracellular region of human glypican-1, and an interpretive article associated with the therapeutic agent ~~an instruction~~ that provides information that binding of the binding molecule to the cancer cells slows growth of the cancer cells that overexpress glypican-1.
6. (currently amended) The system composition of Claim 5, wherein the molecule comprises an antibody that binds to the extracellular region of glypican-1.
  7. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
  8. (Withdrawn) The therapeutic agent of Claim 5, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
  9. (Withdrawn) A method for diagnosing human cancer comprising the steps of contacting a molecule that binds to one of glypican-1 and syndecan-1 with either a body fluid or body tissue, and detecting the molecule bound to glypican-1 or to syndecan-1.
  10. (Withdrawn) The method of Claim 9, wherein the binding molecule comprises an antibody.
  11. (Withdrawn) The method of Claim 10, wherein the antibody is used to detect glypican-1 or syndecan-1 in a body fluid.
  12. (Withdrawn) The method of Claim 10, wherein the antibody is used to image glypican-1 or syndecan-1.
  13. (Withdrawn) A method of slowing growth of human cancer cells comprising administering a molecule that affects glypican-1 by one of binding to an extracellular region of glypican-1, cleaving an extracellular region of glypican-1 and suppressing expression of an extracellular region of glypican-1.
  14. (Withdrawn) The method of Claim 13, wherein the molecule comprises an antibody the binds to the extracellular region of glypican-1.

15. (Withdrawn) The method of Claim 13, wherein the molecule comprises an enzyme that digests a portion of the extracellular region of glypican-1.
16. (Withdrawn) The method of Claim 13, wherein the molecule comprises a nucleic acid molecule that suppresses expression of the extracellular region of glypican-1.
17. (previously presented) The diagnostic kit of claim 1 wherein the human cancer cell is a pancreatic cancer cell or a breast cancer cell.
18. (previously presented) The therapeutic kit of claim 5 wherein the human cancer cells are pancreatic cancer cells or breast cancer cells.